NASDAQ
11.12.25 | 21:59
4,470 US-Dollar
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 04.12. | Foghorn Therapeutics Inc. - 8-K, Current Report | - | SEC Filings | ||
| 03.12. | Stifel initiates Foghorn Therapeutics stock with Buy rating, $12 target | 1 | Investing.com | ||
| FOGHORN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 07.11. | Foghorn Therapeutics Inc. - 8-K, Current Report | - | SEC Filings | ||
| 05.11. | Foghorn Therapeutics GAAP EPS of -$0.25 beats by $0.08, revenue of $8.15M beats by $1.95M | 6 | Seeking Alpha | ||
| 05.11. | Foghorn Therapeutics Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 30.10. | Foghorn advances protein degrader programs for cancer treatment | 1 | Investing.com | ||
| 30.10. | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Announces Updates for Selective ARID1B, Selective CBP and Selective EP300 Degrader Programs | 201 | GlobeNewswire (Europe) | - Data presented at the TPD and Induced Proximity Summit demonstrate that novel Selective ARID1B degrader selectively binds and degrades ARID1B; potentially relevant in up to 5% of all solid tumors... ► Artikel lesen | |
| 30.10. | Foghorn Therapeutics Inc. - 8-K, Current Report | - | SEC Filings | ||
| 16.10. | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Announces Significant Progress for Selective ARID1B Degrader at the 8th Annual TPD and Induced Proximity Summit | 115 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases... ► Artikel lesen | |
| 05.08. | Foghorn: EPS übertrifft Schätzungen um 0,07 $ - Umsatz besser als erwartet | 1 | Investing.com Deutsch | ||
| 05.08. | Foghorn Therapeutics reports Q2 results | 3 | Seeking Alpha | ||
| 05.08. | Foghorn Therapeutics Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 05.08. | Foghorn Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 05.08. | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Provides Second Quarter 2025 Financial and Corporate Update | 269 | GlobeNewswire (Europe) | FHD-909 (LY4050784) Phase 1 dose escalation trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population, is enrolling well and remains on track... ► Artikel lesen | |
| 01.07. | Foghorn Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.06. | Foghorn Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 25.03. | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR Meeting | 176 | GlobeNewswire (Europe) | - FHD-909 (LY4050784) advancing in an ongoing Phase 1 trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population - Oral presentation on preclinical... ► Artikel lesen | |
| 06.03. | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook | 179 | GlobeNewswire (Europe) | First-in-class oral selective SMARCA2 (BRM) inhibitor FHD-909 (LY4050784) continues enrollment in Phase 1 trial for SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary... ► Artikel lesen | |
| 16.12.24 | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities | 231 | GlobeNewswire (Europe) | Objective clinical responses by standard response criteria observed in Phase 1 dose escalation trial for FHD-286 in combination with decitabine in patients with relapsed and/or refractory AML; efficacy... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| STRUCTURE THERAPEUTICS | 67,44 | 0,00 % | Structure Therapeutics Inc.: Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSs | SAN FRANCISCO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| ARCELLX | 72,69 | 0,00 % | Stifel upgrades Arcellx stock, cites buying opportunity after share weakness | ||
| AVIDITY BIOSCIENCES | 71,60 | +0,35 % | Dyne upgraded at Oppenheimer on upcoming trial readout from Avidity | ||
| PRAXIS PRECISION MEDICINES | 267,28 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026 | BOSTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| IMMUNOVANT | 24,810 | 0,00 % | Immunovant: 550-Millionen-Dollar-Kapitalerhöhung und neue Studiendetails | ||
| COGENT BIOSCIENCES | 40,040 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an objective response rate (CR+CRh+PR+CI) of 57% per mIWG criteria and 80% per PPR criteria -- -- Bezuclastinib... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 81,70 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements | Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 14,070 | 0,00 % | Hagens Berman Sobol Shapiro LLP: MoonLake Immunotherapeutics' (MLTX) Stock Crashes 90%, Triggers Lawsuit After Reported Phase 3 Trial Data for Sole Drug Candidate -- Hagens Berman | SAN FRANCISCO, Nov. 28, 2025 /PRNewswire/ -- MoonLake Immunotherapeutics (NASDAQ: MLTX), a clinical-stage biotechnology company, has been hit with a securities... ► Artikel lesen | |
| DYNE THERAPEUTICS | 19,420 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares | WALTHAM, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven... ► Artikel lesen | |
| VERA THERAPEUTICS | 46,020 | 0,00 % | Vera Therapeutics, Inc. - 8-K, Current Report | ||
| MINERALYS THERAPEUTICS | 36,050 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | - Submission of New Drug Application (NDA) for lorundrostat planned for late-2025/Q1 2026 - - Completed enrollment in Explore-OSA trial; topline results anticipated in Q1 2026 - - Conference call... ► Artikel lesen | |
| FULCRUM THERAPEUTICS | 12,800 | 0,00 % | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting | ? Clear dose-response observed, with a robust and clinically meaningful fetal hemoglobin (HbF) induction at the Week 6 timepoint (n=12): mean absolute HbF in the 20 mg cohort increased by 9.9% at... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 87,81 | 0,00 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | WATERTOWN, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 31,550 | 0,00 % | Olema Pharmaceuticals stock price target raised to $45 at H.C. Wainwright | ||
| RECURSION PHARMACEUTICALS | 4,580 | 0,00 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen |
FOGHORN THERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 4,470 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FOGHORN THERAPEUTICS INC finden Sie auf Wallstreet Online.